- In August 2023, Novo Nordisk A/S reached an agreement to acquire Inversago Pharma for up to USD 1.075 billion, contingent upon meeting specific development and commercial milestones. Inversago, based in Montreal, focuses on therapies targeting the CB1 receptor, with the aim of treating obesity, diabetes, and related metabolic disorders
- In March 2023, Sanofi announced a significant 78% reduction in the list price of Lantus (insulin glargine injection) 100 Units/mL in the U.S. In addition, the company introduced a USD 35 cap on out-of-pocket costs for patients with commercial insurance, reaffirming its commitment to providing affordable access to essential medicines
- In March 2023, Diabeloop entered into a partnership with Novo Nordisk to integrate its self-learning algorithm, DBL-4pen, with Novo Nordisk's reusable insulin pens, NovoPen 6 and NovoPen Echo Plus. In doing so, this collaboration aims to improve Multiple Daily Injections (MDI) therapy for Type 2 diabetes patients, with a clinical study planned to assess its effectiveness
- In November 2022, Novo Nordisk and Abbott formed a partnership to improve diabetes management by making Novo Nordisk’s connected insulin pens compatible with the Abbott FreeStyle LibreLink app. In this way, this integration enables users to sync insulin dosages with glucose levels, offering a comprehensive view for optimized diabetes care
- In January 2022, Insulet Corp., based in Boston, announced that the FDA had cleared its new Omnipod 5 system, marking the company’s entry into the automated insulin delivery (AID) market
